FcRn Inhibitors Market By Drug (Efgartigimod, Rozanolixizumab, Nipocalimab, Batoclimab & Late-Stage Candidates, Other FcRn Inhibitors); By Indication (Generalized Myasthenia Gravis [gMG], Chronic Inflammatory Demyelinating Polyneuropathy [CIDP], Immune Thrombocytopenia [ITP], Pemphigus, Warm Autoimmune Hemolytic Anemia [wAIHA], Other Autoimmune Diseases); By Route of Administration (Subcutaneous Administration, Intravenous Administration); By End User (Hospitals, Specialty Clinics, Infusion Centers, Home Care); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

How Are New Indications and Subcutaneous Therapies Accelerating the FcRn Inhibitors Market?

The Global FcRn Inhibitors Market was valued at USD 4.58 billion in 2025 and is projected to reach USD 13.34 billion by 2032, expanding at a CAGR of 16.5% during 2026–2032.

 

FcRn Inhibitors Market refers to the commercial market for drugs that block the neonatal Fc receptor (FcRn) to lower harmful IgG antibodies involved in autoimmune diseases.

 

In the United States, the main FDA-approved FcRn inhibitors include VYVGART (efgartigimod alfa), RYSTIGGO (rozanolixizumab), and IMAAVY (nipocalimab). VYVGART became the first FcRn-blocking therapy approved for generalized myasthenia gravis in 2021, followed by RYSTIGGO in 2023 and IMAAVY in 2025. The treatment class has also expanded beyond myasthenia gravis, with VYVGART Hytrulo receiving FDA approval for chronic inflammatory demyelinating polyneuropathy (CIDP) in 2024.

 

The treatment class addresses a sizeable autoimmune patient population. A U.S. claims analysis estimated myasthenia gravis prevalence at approximately 37 cases per 100,000 people, equivalent to roughly 123,000 patients at the population level used in the study. Another U.S. analysis estimated around 77,000 people were living with CIDP in 2023, with approximately 9,200 new cases diagnosed during the year. These populations form two of the most commercially important patient groups for current FcRn therapies.

 

FcRn inhibitors are differentiated by their ability to reduce circulating IgG antibodies, including harmful autoantibodies involved in several autoimmune diseases. Their commercial use is already expanding, with approximately 19,000 patients worldwide receiving VYVGART by the end of 2025. Within CIDP alone, more than 2,500 patients globally were receiving VYVGART SC by the second quarter of 2025, showing that adoption is extending into newly approved indications.

 

The FcRn inhibitor pipeline remains active as companies pursue additional autoimmune indications and broader patient eligibility. Market expansion therefore depends on new regulatory approvals, movement into diseases beyond gMG, increasing numbers of treated patients, and competition among VYVGART, RYSTIGGO, IMAAVY, and emerging FcRn therapies. Unlike mature treatment classes that rely mainly on established generic use, the FcRn Inhibitors Market still has substantial growth potential from indication expansion and increasing penetration of eligible autoimmune patient populations.

 

Which FcRn Inhibitor Segments Lead the Market and Which Are Advancing Fastest?

By Drug: Efgartigimod Leads as Nipocalimab Accelerates

Leading Subsegment – Efgartigimod: Efgartigimod, marketed as Vyvgart, is a first-in-class neonatal Fc receptor (FcRn) antagonist and serves as the benchmark therapy within the FcRn Inhibitors Market. The drug holds an estimated 68% market share, corresponding to approximately USD 3.11 billion in 2025 sales, and is projected to expand at a 15.8% CAGR during 2026–2032. Its established clinical position, expanding approved indications, and strong physician adoption reinforce efgartigimod’s leadership across FcRn-targeted autoimmune therapies.

Fastest-Growing Subsegment – Nipocalimab: Nipocalimab accounted for approximately 8% of the global FcRn Inhibitors Market in 2025, representing a market value of around USD 0.37 billion. The drug is projected to expand at the fastest CAGR of approximately 24.8% through 2032. As a first-in-class, fully human IgG1 monoclonal antibody, nipocalimab acts as a targeted neonatal Fc receptor (FcRn) inhibitor, supporting its growing role across FcRn-mediated autoimmune disorders and strengthening its commercial position within the expanding global FcRn inhibitors market.

 

By Indication: gMG Leads Revenue as wAIHA Expands Fastest

Leading Subsegment – Generalized Myasthenia Gravis: Generalized myasthenia gravis (gMG) accounts for approximately 62% of the FcRn Inhibitors Market, representing nearly USD 2.84 billion in 2025 and projected to expand at an estimated 14.8% CAGR during 2026–2032. FcRn inhibitors are increasingly used in gMG treatment because they accelerate the clearance of pathogenic immunoglobulin G (IgG) autoantibodies responsible for disrupting communication at the neuromuscular junction. Growing clinical adoption of targeted antibody-lowering therapies is strengthening the role of FcRn inhibitors in long-term gMG management.

Fastest-Growing Subsegment – Warm Autoimmune Hemolytic Anemia: Warm autoimmune hemolytic anemia (wAIHA) represents an emerging indication within the FcRn Inhibitors Market, accounting for an estimated 3% share, equivalent to approximately USD 0.14 billion in 2025, and is projected to expand at about 25.5% CAGR through 2032. wAIHA is an IgG-mediated autoimmune disorder in which pathogenic IgG autoantibodies attach to red blood cells at body temperature and trigger premature extravascular hemolysis. FcRn inhibition can lower circulating pathogenic IgG levels, creating a targeted therapeutic opportunity for wAIHA management.

 

By Route of Administration: Subcutaneous Delivery Leads Adoption and Growth

Leading and Fastest-Growing Subsegment – Subcutaneous: Subcutaneous administration is a major growth area within the FcRn Inhibitors Market, accounting for approximately 58% of the market, valued at USD 2.66 billion in 2025, and projected to expand at an 18.3% CAGR during 2026–2032. Subcutaneous FcRn inhibitors provide targeted delivery that reduces circulating immunoglobulin G (IgG) levels while offering greater convenience than intravenous infusions. Easier administration, reduced infusion-center dependence, and improved treatment flexibility are supporting wider use across IgG-mediated autoimmune disorders.

 

By End User: Hospitals Anchor Treatment as Home Care Accelerates

Leading Subsegment – Hospitals: Hospitals account for approximately 55% of the FcRn Inhibitors Market, representing around USD 2.52 billion in 2025, and are projected to expand at a 15.1% CAGR through 2032. Hospitals and specialized outpatient infusion centers remain central to the administration and clinical monitoring of FcRn inhibitors, including efgartigimod and rozanolixizumab, particularly for patients with autoimmune neuromuscular disorders requiring specialist supervision, scheduled dosing, treatment-response assessment, and management of therapy-related complications.

Fastest-Growing Subsegment – Home Care: Home care accounted for approximately 7% of the FcRn Inhibitors Market, valued at about USD 0.32 billion in 2025, and is projected to grow at a 21.5% CAGR during 2026–2032. FcRn inhibitors such as rozanolixizumab (Rystiggo), efgartigimod, and nipocalimab are increasingly being administered through home- and outpatient-based care pathways for autoimmune disorders including generalized myasthenia gravis (gMG). Greater treatment convenience and reduced dependence on hospital-based administration are supporting faster adoption of home-based FcRn inhibitor therapy.

 

By Geography: North America Leads as Asia-Pacific Adoption Accelerates

Leading Subsegment – North America: North America accounted for approximately 49% of the global FcRn Inhibitors Market in 2025, representing nearly USD 2.24 billion, and is projected to expand at a 15.3% CAGR through 2032. The region leads global adoption of Neonatal Fc receptor (FcRn) inhibitors, supported by early approvals, broader treatment availability, and increasing clinical use across autoimmune disorders. Strong pharmaceutical activity and expanding use of FcRn-targeted therapies continue to reinforce North America’s leadership in the FcRn Inhibitors Market.

Fastest-Growing Subsegment – Asia-Pacific: The Asia-Pacific FcRn Inhibitors Market accounted for approximately 20% of the global market in 2025, valued at around USD 0.92 billion, and is projected to record the fastest regional CAGR of approximately 20.4% during 2026–2032. Growing adoption of neonatal Fc receptor (FcRn) inhibitors for targeted treatment of autoimmune disorders, expanding clinical availability, improving diagnosis rates, and wider introduction of novel antibody-based therapies are accelerating market expansion across major Asia-Pacific healthcare systems.

 

How Are FDA Approvals and Clinical Pipelines Expanding the FcRn Inhibitor Market Beyond gMG?

FDA-Approved FcRn Inhibitors:

• VYVGART / VYVGART HYTRULO (efgartigimod) is an FcRn blocker used in antibody-mediated neurological disease. VYVGART HYTRULO is FDA-approved for adults with anti-AChR-positive generalized myasthenia gravis (gMG) and, since June 2024, for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). The CIDP formulation is administered subcutaneously once weekly, extending FcRn therapy into a major chronic neuropathy market.

• RYSTIGGO (rozanolixizumab-noli) received FDA approval on June 26, 2023 for adults with gMG who are anti-AChR- or anti-MuSK-antibody positive. It is delivered by subcutaneous infusion once weekly for a six-week treatment cycle, giving the market an additional non-IV FcRn therapy.

• IMAAVY (nipocalimab-aahu) received its initial FDA approval on April 29, 2025 for gMG in adults and adolescents aged 12 years and older who are anti-AChR- or anti-MuSK-positive. In August 2026, the FDA expanded its use to warm autoimmune hemolytic anemia (wAIHA) in patients aged 12 years and older who are receiving or have previously received corticosteroids. In the pivotal wAIHA study, 24% of patients receiving the 30 mg/kg regimen achieved a durable hemoglobin response versus 8% with placebo. The approval was particularly important commercially because IMAAVY became the first FDA-approved therapy specifically for wAIHA.

 

FcRn Inhibitor Pipeline:

• IMVT-1402 (imeroprubart) is one of the most advanced next-generation FcRn programs. As of 2026, Immunovant has clinical programs spanning Graves' disease, myasthenia gravis, CIDP, difficult-to-treat rheumatoid arthritis and Sjögren's disease, with several programs in Phase 3 or potentially registrational development. In difficult-to-treat rheumatoid arthritis, reported Week-16 response rates included 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70. Development in cutaneous lupus was discontinued after the study failed its primary endpoint, illustrating both the opportunity and indication-specific clinical risk within the FcRn pipeline.

• VRDN-006 has completed a Phase 1 healthy-volunteer study, where Viridian reported IgG reductions consistent with the FcRn class while largely sparing albumin and LDL. VRDN-008, a bispecific and half-life-extended FcRn inhibitor, entered Phase 1 after its IND was cleared in January 2026; the program is designed to achieve more durable IgG lowering and potentially longer dosing intervals.

• Batoclimab was previously a major late-stage FcRn candidate, but its development was discontinued in 2026 after two Phase 3 thyroid eye disease trials failed to meet their primary endpoints. Immunovant subsequently shifted resources toward IMVT-1402.

 

How Are Leading FcRn Companies Expanding Through Commercial Adoption, New Indications, and Delivery Innovation?

argenx – Commercial Leader Through the VYVGART FcRn Franchise

argenx is the strongest commercial participant in the FcRn inhibitor market through VYVGART (efgartigimod) and VYVGART HYTRULO, which target FcRn to accelerate removal of pathogenic IgG antibodies. The franchise has established a broad commercial base across generalized myasthenia gravis (gMG) and CIDP, supported by intravenous, subcutaneous, and pre-filled syringe administration options. In 2025, argenx reported USD 4.15 billion in product net sales, up approximately 90% from USD 2.19 billion in 2024. Around 19,000 patients globally received VYVGART during 2025, while the company entered 2026 with 10 ongoing registrational trials. The growing number of formulations and indication-expansion programs positions efgartigimod as the current commercial benchmark for FcRn therapy.

UCB – RYSTIGGO Builds a Growing Subcutaneous FcRn Position in gMG

UCB competes through RYSTIGGO (rozanolixizumab-noli), a subcutaneously administered anti-FcRn monoclonal antibody approved for adults with anti-AChR- or anti-MuSK-positive gMG. Its commercial performance has accelerated as treatment uptake expands across the United States, Europe, and Japan. RYSTIGGO generated EUR 332 million in 2025 net sales, up 65% from EUR 202 million in 2024, while UCB reported that more than 2,400 gMG patients had received the therapy by the end of 2025. Sales reached another EUR 192 million in the first half of 2026, indicating continued adoption of FcRn-targeted subcutaneous therapy.

Johnson & Johnson – Nipocalimab Expands FcRn Therapy Beyond Neurology

Johnson & Johnson has strengthened its position through IMAAVY (nipocalimab-aahu), a fully human FcRn-blocking monoclonal antibody. The FDA approved IMAAVY in April 2025 for adults and adolescents aged 12 years and older with anti-AChR- or anti-MuSK-positive gMG. Clinical development showed sustained disease control for up to 20 months, broadening its relevance for long-term treatment.

Its competitive importance increased further in August 2026, when IMAAVY became the first FDA-approved treatment specifically for warm autoimmune hemolytic anemia (wAIHA). In the pivotal program, patients showed a mean hemoglobin increase of 1 g/dL as early as Week 1, while responders receiving the 30 mg/kg regimen reached their first hemoglobin response in a median 4.1 weeks versus 12.1 weeks with placebo. Expansion into hematology demonstrates how FcRn inhibition can generate revenue beyond the current gMG-centered market.

Other Companies Shaping the FcRn Pipeline:

• Immunovant/Roivant: Developing IMVT-1402 (imeroprubart) across Graves' disease, MG, CIDP, Sjögren's disease, and difficult-to-treat rheumatoid arthritis; Phase 3 programs are underway in several indications.

• Viridian Therapeutics: Advancing next-generation VRDN-006 and VRDN-008 programs aimed at achieving strong IgG lowering with potentially improved dosing durability.

• Zai Lab: Supports the commercialization and development of efgartigimod in Greater China, extending FcRn therapy access within a major Asia-Pacific autoimmune treatment market.

• Immunovant's batoclimab program: Helped establish clinical proof for FcRn inhibition across autoimmune diseases, although development emphasis has subsequently shifted toward the next-generation IMVT-1402 platform.

• Emerging FcRn developers: Several biotechnology companies are investigating longer-acting antibodies, Fc fragments, and alternative administration technologies intended to reduce treatment frequency and improve convenience.

 

Analyst Commentary: How Will Broader Indications and Delivery Innovation Shape the Next Phase of FcRn Growth?

The FcRn inhibitors market is shifting from a gMG-focused treatment class toward a broader autoimmune therapeutics platform. The strongest growth opportunities are emerging from indication expansion into CIDP, warm autoimmune hemolytic anemia, Graves’ disease, Sjögren’s disease, and other IgG-mediated disorders. Subcutaneous formulations, pre-filled delivery systems, longer-acting candidates, and deeper IgG suppression are becoming key competitive differentiators.

 

FcRn Inhibitors Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 4.58 Billion
Revenue Forecast in 2032	USD 13.34 Billion
Overall Growth Rate	CAGR of 16.5% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million/Billion, CAGR (2026 – 2032)
Segmentation	By Drug, By Indication, By Route of Administration, By End User, By Geography
By Drug	Efgartigimod, Rozanolixizumab, Nipocalimab, Batoclimab and Late-Stage Candidates, Other FcRn Inhibitors
By Indication	Generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Immune Thrombocytopenia (ITP), Pemphigus, Warm Autoimmune Hemolytic Anemia, Other Autoimmune Diseases
By Route of Administration	Subcutaneous Administration, Intravenous Administration
By End User	Hospitals, Specialty Clinics, Infusion Centers, Home Care
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Expansion of FcRn inhibitors beyond generalized myasthenia gravis, increasing autoimmune disease treatment demand, new regulatory approvals, growing treated-patient populations, expansion into CIDP and warm autoimmune hemolytic anemia, increasing adoption of subcutaneous administration, development of next-generation FcRn therapies, and broader clinical pipelines targeting additional IgG-mediated autoimmune diseases
Customization Option	Available upon request